Lower dose vs standard dose HIPEC for pseudomyxoma peritonei
Treatments studied
Part of Cancer clinical trials.
This trial compares a lower dose of heated chemotherapy (HIPEC) given during surgery to a standard dose for patients with pseudomyxoma peritonei (a condition where jelly-like mucus builds up in the abdomen). The goal is to see if the lower dose works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of pseudomyxoma peritonei (jelly belly) from a mucinous tumor of the appendix (low or high grade).
- You are able to have surgery to remove all visible disease (your doctor will ensure this is possible).
- You are 16 years or older and can give informed consent.
- You are in good daily functioning (ECOG 0 or 1, meaning you can do normal activities without assistance).
- You have not had previous cytoreductive surgery or HIPEC.
- You are not pregnant or breastfeeding, and have no severe allergies to the chemotherapy drug (mitomycin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different schedules of heated chemotherapy (HIPEC) after surgery for pseudomyxoma peritonei (a rare appendix cancer that spreads in the abdomen). It may help determine whether one or three cycles of HIPEC is better for controlling the disease.
This trial tests a chemotherapy combination (capecitabine and cyclophosphamide) given before surgery for people with a large amount of pseudomyxoma peritonei (PMP). The goal is to see if it can shrink the tumor and make surgery more effective.
This trial tests a vaccine for people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that has come back or cannot be removed by surgery. The vaccine is designed to help the immune system fight the cancer. It is for people whose tumor has a specific genetic change (GNAS mutation) and who have no other standard treatment options.
This study looks at how cancers that spread along the belly lining (“peritoneal surface malignancies”) behave and how different treatment strategies may work. It may help improve how doctors select and test treatments for people who are candidates for CRS-HIPEC, a specific cancer surgery approach.
This trial tests whether the drug metformin (a common diabetes pill) can help control pseudomyxoma peritonei, a rare abdominal cancer. It is for people whose cancer has come back or cannot be surgically removed, and who aren't planning a major surgery with heated chemotherapy at this time.
This trial is a registry study that follows people with certain abdominal (peritoneal) cancers who are planned for surgery plus heated chemotherapy placed inside the abdomen. It mainly helps doctors learn about outcomes and care patterns for these treatments.
Hear when a new Pseudomyxoma Peritonei trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.